Tuvalu settles for ninth place in men’s volleyball

first_imgBoth teams finished fifth in their pools to play for the ninth position.Tuvalu proved too strong for Solomon Islands winning the first set in a close encounter 25-19. Solomon Islands played hard in the second set but lacked defence letting Tuvalu spike right through to win the round by a big margin 25-15. Tuvalu maintained pace with their blocks and ball placement to win the third set 25-19. Solomon Islands have finished their Pacific Games campaign at the bottom on 10th place.last_img

Ison and Lim Finish Top-14 to Lead Bulldogs at Hawkeye Invite

first_imgFreshman Tim Lim finished a stroke back from Ison to place tied for 14th. Lim shot a two-over-par 74 on the final day for a total score of 149 (75-74). Results Story Links Senior Drew Ison fired a one-over-par, 73, to finish tied for 11th-place with a team-best total score of 148 (75-73). Chase Wicklund, who played as an individual, recorded a total score of 167 (80-87). The Bulldogs registered a 302 for a final score of 602 (300-302) and moved up five spots to finish tied for sixth with Minnesota, who recorded a 317 in the second round. Iowa State managed to hold on to its lead to take home the team title with a score of 583 (280-303). Host Iowa finished runner-up one shot behind the Cyclones with a score of 384 (285-299). Sophomore Kyle MacDonald carded a three-over, 75, on the 7,239-yard, par-72 course to finish tied for 30th with a score of 152 (77-75). Tommi Avant carded an 80 on the final day to finish with a total score of 154 (74-80), while Arjun Reddy closed out the team’s performance with a total score of 160 (76-84). “I am extremely proud of the team and how we played today. The conditions were so tough. It was absolutely freezing out with strong winds and rain,” said Drake head coach Matt Lewis. “We had the second-best score of the day which shows our mental toughness and character. We also moved up five spots and had a strong finish.” IOWA CITY, Iowa – The Drake University men’s golf team put together the second-best score of the day to finish tied for sixth place at the two-day, 36-hole Hawkeye Invitational. The Bulldogs will have nearly 10 days to make final preparations for the MVC Championship on April 23-24 at Cape Girardeau, Mo. Print Friendly Versionlast_img read more

FDA defends plan to regulate labdeveloped tests

first_img Click to view the privacy policy. Required fields are indicated by an asterisk (*) Email A move by the U.S. Food and Drug Administration (FDA) to regulate diagnostic tests developed in thousands of laboratories is picking up steam—and drawing fire. The agency recently notified Congress that it plans to regulate some of these so-called laboratory developed tests (LDTs)—which, unlike tests marketed by diagnostic manufacturers, don’t currently require FDA approval. FDA has not yet released a draft guidance on the matter, but at a hearing yesterday, members of the U.S. House of Representatives Energy & Commerce Committee’s health subcommittee raised questions about the agency’s authority to regulate these tests, its motivation for doing so, and the potential impact of such regulations on the diagnostic industry.Doctors use diagnostic tests to determine which patients are at risk for developing a disease and which would benefit from a treatment. And while companies offer FDA-approved kits for many of these uses, clinical labs often design and offer their own. According to the American Clinical Laboratory Association (ACLA), more than 11,000 laboratories are authorized to develop and perform LDTs, and the majority of them do.FDA has had the authority to regulate LDTs—and all in vitro diagnostics—since 1976, explained Jeffrey Shuren, director of FDA’s Center for Devices and Radiological Health, at the hearing. But the agency has so far exercised “enforcement discretion” and has not required that labs manufacturing these tests seek its approval. Labs have instead been regulated by the Centers for Medicare & Medicaid Services through the 1988 Clinical Laboratory Improvement Amendments (CLIA). But LDTs aren’t what they used to be, Shuren told the subcommittee. They’re manufactured in large quantities and are increasingly removed from the health care centers and doctors who order them. They are also increasingly complex, relying on sophisticated software to interpret results. Although CLIA ensures that labs perform a test properly, it doesn’t address the clinical validity of the test itself—how accurately it measures a patient’s condition. “We have a responsibility to provide patients with greater certainty,” Shuren said.That’s why FDA has for years been angling to regulate LDTs and is now developing a draft guidance for labs to seek its approval. The new requirements wouldn’t apply to all tests. Those that FDA considers “low-risk,” those that diagnose rare diseases, and those that have no FDA-approved equivalent would continue to enjoy enforcement discretion. But for the rest, labs would have to submit data proving their validity. But it’s not yet clear how many labs would be subject to the new requirements.Some lawmakers and stakeholders balk at the thought of FDA’s increased involvement. Alan Mertz, president of ACLA and a witness at the hearing, argued that the proposed regulations would discourage labs from developing innovative new tests and prevent them from adjusting the tests quickly for new uses. Mertz, along with several representatives, also challenged FDA’s authority to regulate LDTs, arguing that they are not “devices” but rather services provided to a patient, and are already regulated effectively under CLIA.But others welcome FDA’s move to raise the regulatory bar. Christopher Newton-Cheh, a cardiologist at Massachusetts General Hospital in Boston who testified on behalf of the American Heart Association, called the current system “completely opaque.” Doctors often aren’t aware if the test they order is FDA-approved, and inaccurate results increase the risk that patients will undergo unnecessary treatment or be excluded from a treatment based on bad information. “This is the right thing to do for patients,” he said.FDA may release its draft guidance on or after 29 September. Once the agency finalizes the guidance, it intends to phase in the new review process over 9 years.center_img Sign up for our daily newsletter Get more great content like this delivered right to you! Country Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwelast_img read more